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Care in Boston, MA. At the time of SCT, these patients ranged in
age from 2 to 11 months old. Conditioning regimens prior to
transplant all contained a combination of intravenous busulfan,
cytoxan, and an additional lymphocytotoxic agent such as ﬂudara-
bine, alemtuzumab or anti-thymocyte globulin. Three of the ﬁve
patients required intubation at a median of day 4 post transplant.
All but one patient was successfully extubated at a median of 31
days post transplant. That patient was removed from life support
due to multi-organ failure at day  44 having not yet engrafted.
The remaining four patients engrafted at a median of 40 days post
transplant. Two died after day  100, one of a bacterial infection
and the other of enteroviral myocarditis. Two long-term survivors
are well and developing appropriately at 9 months and 33 months
post-transplant. Infants with osteopetrosis seem to have an in-
creased risk of pulmonary and infectious complications. Mothers of
these patients are recently post-partum and families are often far
from home at a tertiary care center. Nursing implications for the
care of the osteopetrosis patient during SCT include vigilant mon-
itoring of respiratory status, vital signs and laboratory results.
Extensive family support and education regarding the disease and
the transplant process is also essential for the care of these children
and their families.
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CARDIAC AMYLOIDOSIS AND STEM CELL TRANSPLANTATION: WHAT
NURSES NEED TO KNOW
Oliver, T.D.1 1The University of Texas MD Anderson Cancer Center,
Houston, TX.
Primary (AL) amyloidosis with cardiac involvement is commonly
seen in patients with multiple myeloma (MM). More than twenty-
ﬁve percent of patients with cardiac amyloidosis will develop heart
failure. Thus, as more patients with MM seek stem cell transplan-
tation for treatment of their disease, health care providers can
expect to see more complications related to cardiac amyloidosis. In
order to better prepare nurses caring for MM patients with cardiac
amyloidosis, a teaching poster has been developed that increases
stem cell transplant nurses’ knowledge about cardiac amyloidosis.
The educational poster focuses on improving early recognition
and management of AL amyloidosis through increased nursing
knowledge of signs and symptoms of cardiac amyloidosis. Early
signs of cardiac amyloid involvement include dyspnea, fatigue,
peripheral edema, systolic murmur, dysrhythmia, and postural hy-
potension. Nurses should be prepared to adjust patient daily rou-
tines in order to provide supportive treatment for hypotension and
congestive heart failure. It is important for nurses to become more
aware of the signs and symptoms of AL amyloidosis in order to
alert primary care teams of changes in patient condition, inquire
about telemetry monitoring and cardiology consults. Therefore,
the ultimate goals of increasing knowledge among nurses caring for
stem cell transplant patients with cardiac amyloidosis are better
symptom management, appropriate multidisciplinary participation
in care, and positive patient outcomes. These goals are attainable
when nurses more completely understand their patients’ medical
conditions and increased knowledge may be evaluated through
positive post-test results after presentation of the educational
poster.
A case presentation of a patient with multiple myeloma and
cardiac amyloidosis who underwent stem cell transplantation will
illustrate these teaching points and nursing issues as well as high-
light the ethics surrounding stem cell transplantation and cardiac
amyloidosis.
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PRIMARY CARE IN A TERTIARY SETTING OF STEM CELL TRANSPLAN-
TATION
Rhodes, B.A.1 1M.D.Anderson Cancer Center, Houston, TX.
The traditional role of a nurse practitioner is in a primary care
setting; however nurse practitioners are prepared by education and
clinical training to function in a variety of settings. This poster will
explore how a nurse practitioner in a major cancer referral center
provides comprehensive care and has a positive impact on patients
and staff in the complex setting of hematopoietic transplantation.
Setting: Major Cancer Referral Center, Department of Stem
Cell Transplantation and Cellular Therapy
Staff: Adult Nurse Practitioner (ANP), RNs, LVNs, Pharma-
cists, Physicians, and Patient Service Coordinators
Roles of Nurse Practitioner: Patient Care - Provides quality,
evidence-based patient care. Patient population includes a variety
of complex cancer patients with multiple myeloma, lymphoma,
leukemia, aplastic anemia, melanoma, glioblastoma, and neuroblas-
toma that are undergoing autologous or allogeneic hematopoeitic
cell transplantation or participating in vaccination clinical trials.
ANP performs comprehensive health assessments, identiﬁes nor-
mal and abnormal characteristics, develops treatment plan, initiates
appropriate care and continuously evaluates outcomes. Collabo-
rates with multidisciplinary health care team of nurses, physicians,
pharmacist, social worker, case manager, nutritionist and chaplain.
Educator - Provides education to hospital and nursing staff,
other healthcare workers, students, patients, and patient’s family
members regarding prevention and management of symptoms re-
lated to the transplant process. Conducts lectures and inservices on
a variety of transplant-related topics within the hospital/clinic
environment as well as at local and national conferences.
Research and Quality Improvement - Participates in a variety
of research protocols including stem cell research and development
of new therapies for transplant patients. Serves as an active member
of the quality improvement committee of stem cell and cellular
therapy that monitors for trends, outcomes, and adverse effects to
improve processes and positively affect patient care.
Outcomes - High level of patient satisfaction, documented by
quarterly patient satisfaction surveys
Decreased number of hospitals admissions and length of hospital
stays
Increased revenue of outpatient clinic.
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SURVEILLANCE, EVALUATION AND MANAGEMENT OF PASSENGER
LYMPHOCYTE SYNDROME
Rice, J.M.1, Sirilla, J.A.1, Krugh, D.W.1, Crawford, R.1,
Benson, D.M.1, Devine, S.M.1 1Ohio State University James Cancer
Hospital and Solove Research Institute, Columbus, OH.
Sudden immune hemolysis in the setting of ABO and non-ABO
mismatched allogeneic stem cell transplantation is a potentially
life-threatening complication that requires early recognition and a
multidisciplinary care team to deliver immediate lifesaving mea-
sures. The BMT Program at The Ohio State University James
Cancer Hospital developed a Plan of Care providing guidelines for
surveillance, evaluation and management of immune hemolysis
related to Passenger Lymphocyte Syndrome.
Surveillance consists of a direct antiglobulin testing (DAT) per-
formed on day 7, 14 and 21 and monitoring of donor anti-
body in the patient’s ABO reverse typing or antibody screen. If a
donor has a clinically signiﬁcant RBC antibody, the patient is
antigen typed for the respective antigen.
Discovery of a positive DAT and the presence of the donor’s
antibody, an initial hemolytic evaluation is performed including:
lactate dehydrogenase (LD), total and direct bilirubin (BILI), hap-
toglobin and hemoglobin/hematocrit (H/H).
If the hemolytic evaluation is negative, H/H every 12 hours and
BILI, LD daily are performed until day 28 to monitor for
hemolysis.
If the hemolytic evaluation is positive without signiﬁcant hemo-
lysis (i.e., 2 g/dL drop in hemoglobin), H/H every 12 hours and
BILI, LD, HAPT, urinalysis daily are performed until day 28.
RBC exchange is considered in the setting of laboratory evidence
of hemolysis when: a patient has related, signiﬁcant physical symp-
toms, a  2 g/dL in hemoglobin in 24 hour period, or impairment
of creatinine clearance and/or hemoglobinuria.
Order sets have been implemented through electronic ordering
pathways. Ongoing, prospective evaluation of the strategy is un-
derway.
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